These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30188978)

  • 1. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
    Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
    Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
    Dorlo TPC; Kip AE; Younis BM; Ellis SJ; Alves F; Beijnen JH; Njenga S; Kirigi G; Hailu A; Olobo J; Musa AM; Balasegaram M; Wasunna M; Karlsson MO; Khalil EAG
    J Antimicrob Chemother; 2017 Nov; 72(11):3131-3140. PubMed ID: 28961737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
    Dorlo TP; Huitema AD; Beijnen JH; de Vries PJ
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3864-72. PubMed ID: 22585212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
    Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
    Palić S; Kip AE; Beijnen JH; Mbui J; Musa A; Solomos A; Wasunna M; Olobo J; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2020 Nov; 75(11):3260-3268. PubMed ID: 32780098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM; Mbui J; Mohammed R; Olobo J; Ritmeijer K; Alcoba G; Muthoni Ouattara G; Egondi T; Nakanwagi P; Omollo T; Wasunna M; Verrest L; Dorlo TPC; Musa Younis B; Nour A; Taha Ahmed Elmukashfi E; Ismail Omer Haroun A; Khalil EAG; Njenga S; Fikre H; Mekonnen T; Mersha D; Sisay K; Sagaki P; Alvar J; Solomos A; Alves F
    Clin Infect Dis; 2023 Feb; 76(3):e1177-e1185. PubMed ID: 36164254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
    Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
    Verrest L; Roseboom IC; Wasunna M; Mbui J; Njenga S; Musa AM; Olobo J; Mohammed R; Ritmeijer K; Chu WY; Huitema ADR; Solomos A; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2023 Nov; 78(11):2702-2714. PubMed ID: 37726401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
    Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
    J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
    Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Resistance of
    Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
    Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
    Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
    PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.
    Patterson S; Wyllie S; Norval S; Stojanovski L; Simeons FR; Auer JL; Osuna-Cabello M; Read KD; Fairlamb AH
    Elife; 2016 May; 5():. PubMed ID: 27215734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
    Pandey K; Ravidas V; Siddiqui NA; Sinha SK; Verma RB; Singh TP; Dhariwal AC; Das Gupta RK; Das P
    Am J Trop Med Hyg; 2016 Nov; 95(5):1100-1105. PubMed ID: 27645786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.